Navigation Links
sanofi-aventis: Strong Performance of Growth Platforms in Q1 2011
Date:4/28/2011

Sales from new products (Jevtana® and Multaq®) totaled euro 111 million versus euro 24 million in Q1 2010.

Net sales for Jevtana® (cabazitaxel) were euro 48 million in the first quarter of 2011 mostly generated in the U.S. This new anti-cancer agent was launched in the U.S. in July 2010 for patients with metastatic hormone-refractory prostate cancer previously treated with a docetaxel-based therapy. The patient share of Jevtana® in the U.S. in second line metastatic hormone-refractory prostate cancer reached 54% in February (IntrinsiQ February 2011). In March 2011, Jevtana® received marketing authorization from the European Commission. The first launch of Jevtana® in the EU occurred in Germany in April 2011.

First-quarter net sales of Multaq® were euro 63 million (versus euro 24 million in Q1 2010), of which euro 44 million was generated in the U.S. Sales in Western Europe reached euro 17 million in the period. In January 2011, sanofi-aventis issued a Dear Health Care Provider Letter worldwide. The FDA also issued a Drug Safety Communication on hepatic events reported in patients treated with Multaq®. The revised product information was updated accordingly. The benefit/risk assessment of Multaq® by the EMA is ongoing. In the U.S. Multaq® received new Tier 2 unrestricted status with two major Managed Care accounts (United Healthcare Medicare and Commercial).

Worldwide presence(1) of Plavix®/Iscover®

First-quarter worldwide presence of Plavix® was euro 1,734 million, up 0.4% impacted by generic competition in Europe. In the U.S., Plavix® sales were euro 1,200 million, up 7.2% (net sales consolidated by Bristol-Myers Squibb). The product continued its success in Japan and China with a sales increase of +28.8% (euro 139 million) and +31.1% (euro
'/>"/>

SOURCE sanofi-aventis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation
2. Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile
3. Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile
4. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
5. AspenBio Pharma Reports Strong Results with Appendicitis Triage Blood Test from Large Multiple Hospital Study
6. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
7. HealthMedias Strongest Single Quarter Results: Growth Driven by Product Enhancements, New Partnerships
8. SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents
9. US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings
10. Groundbreaking American Journal of Play from Strong National Museum of Play(R) Premiers July 2008
11. Seventy Years Old and Going Strong With Down Syndrome and No Dementia: The Case of Mr. C Causes Major Interest in the Scientific Community
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX ), ... commercialization of innovative therapies for the treatment of acute ... officer Howie Rosen will be presenting at ... Tim Morris will be presenting at JMP Securities ... as follows: Jefferies 2015 Healthcare Conference Date: ...
(Date:5/21/2015)... Research and Markets ( ... "Market Assessment of Respiratory Diagnostics in the ... offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,This research service ... market in the United States ... service provides detailed analysis of the current and ...
(Date:5/21/2015)... WASHINGTON , May 21, 2015 ... following statement regarding the Medicare Part D offsets ... Century Cures initiative: "If the 21st Century ... billions from America,s premier health program – Medicare ... it may yield down the road. ...
Breaking Medicine Technology:AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences In June 2United States and Europe Respiratory Diagnostics Market Assessment 2015 2
... France, Oct. 8 Vical Incorporated (Nasdaq: ... new nonclinical data,demonstrating that the company,s Vaxfectin(R) adjuvant ... disease vaccines and,peptide-based cancer vaccines. Alain P. Rolland, ... will present the data today,Wednesday, October 8, at ...
... 7 Prometheus Laboratories Inc., a,specialty pharmaceutical ... PROMETHEUS(R) IBS Diagnostic, the first and only ... findings suggest measurable,differences in the expression of ... non-IBS patients. The identification of these biomarkers,combined ...
Cached Medicine Technology:Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 2Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 3
(Date:5/24/2015)... 2015 ProPin is a set of ... X. Utilize ProPin to pin point locations on a map, ... , ProPin allows users to choose from 30 simplistic presets ... With on-screen controls, video editors can easily manipulate ProPin presets as ... mark with absolute ease. , Using ProPin is easy, simply drag ...
(Date:5/24/2015)... WI (PRWEB) May 24, 2015 ... Health System CEO - The ... and honored at the fourth annual ... April 15 at Geneva National in ... school): ,     -Badger High School,         Jonathan ...
(Date:5/23/2015)... On May 13, Nithyananda Yoga Foundation organized a ... learned through meditation and initiation at Special Holistic School ... Yogamaatha, a nine-year-old girl from North Carolina, stunned an ... the 2015 Business Advocacy Summit at Capitol Hill in ... In a demonstration that lasted three hours, Yogamaatha was ...
(Date:5/23/2015)... 2015 On Wednesday, May 20, 2015, ... has been the target of a sophisticated cyberattack,” and ... company’s ongoing Information Technology (IT) security efforts in the ... The most notable attack on health insurers was reported ... nation’s second largest health insurer, revealed that they had ...
(Date:5/23/2015)... A live auction will be held to sell over 5,200 ... medical facilities around the United States. Various types of ... exam and much more. , The live auction will ... at 9:00am CDT each day. The equipment is at their ... IL 60160. Anyone can participate in the auction including ...
Breaking Medicine News(10 mins):Health News:Developers at Pixel Film Studios Release ProPin for Final Cut Pro X. 2Health News:Mercy Foundation Honors 16 Students for Making a Difference - Mercy Health System Javon Bea 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 3Health News:One Headline Making Cyber Attack Sparks Discovery of Another 2Health News:One Headline Making Cyber Attack Sparks Discovery of Another 3Health News:One Headline Making Cyber Attack Sparks Discovery of Another 4Health News:Over 5,200 Lots of Medical Equipment Will Be Sold by Live Auction 2
... for Childhood Cancer Research (NCCCR), a newly established division of Nemours ... in Wilmington, DE, has secured $1,020,000 in external funding for awards ... ... January 8, 2009-- The research team at the Nemours Center ...
... may reduce risk of cardiovascular disease , , THURSDAY, Jan. ... the millions of American men and women with type ... the day may be symptoms of obstructive sleep apnea, ... diabetics. , Based on strong preliminary evidence linking the ...
... Minnesota receives $20,000 to support local programs as part ... Special Olympics Minnesota recently received $20,000 ... Special Olympics International,s new national program. Project UNIFY is ... States in an effort to promote school communities where ...
... While the U.S. Food and Drug Administration Drug has quickened ... diseases for which new therapeutics are being developed has resulted ... for the Study of Drug Development. , The average time ... years in the 2005-07 period, but longer average clinical phase ...
... Limited (Nasdaq: WCRX ) announced today that ... Conference on Tuesday, January 13, 2009 at 3:00 p.m. ... Boissonneault, President and Chief Executive Officer and Paul Herendeen, ... will be webcast live for all interested parties at ...
... today announced that the second annual Health IT ... content partnership with Health Industry Insights, an IDC company, ... in Phoenix, Arizona from April 29-May 1, 2009. Originally ... moving to the four-diamond Phoenix resort in order to ...
Cached Medicine News:Health News:Nemours Center for Childhood Cancer Research Receives Over $1 Million in Grants for Cancer Research in 2008 2Health News:Nemours Center for Childhood Cancer Research Receives Over $1 Million in Grants for Cancer Research in 2008 3Health News:Nemours Center for Childhood Cancer Research Receives Over $1 Million in Grants for Cancer Research in 2008 4Health News:Doctors Urged to Screen Diabetics for Sleep Apnea 2Health News:Doctors Urged to Screen Diabetics for Sleep Apnea 3Health News:Special Olympics Minnesota Launches Project UNIFY to Energize Youth 2Health News:New drug development still takes 8 years despite faster FDA review, according to Tufts CSDD 2Health News:CrossTech Forums Announces Health IT Insight 2009 Moving to Arizona Grand Resort in Phoenix; Executive Summit to Take Place April 29-May 1 2Health News:CrossTech Forums Announces Health IT Insight 2009 Moving to Arizona Grand Resort in Phoenix; Executive Summit to Take Place April 29-May 1 3
A simple, in-office test for the detection of mononucleosis. Easy to use with fast, accurate results within minutes....
... The Wampole PreVue B. Burgdorferi Antibody ... membrane assay for the qualitative presumptive (first ... to B. burgdorferi in human serum or ... use and relative accuracy make the Wampole ...
Comprehensive range of integrated implants and instruments including - Basic, Small, Mini, Pelvic and Foot Sets....
Comprehensive range of integrated implants and instruments including - Basic, Small, Mini, Pelvic and Foot Sets....
Medicine Products: